Related Experiment Video
Updated: Jun 20, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
[Natalizumab in multiple sclerosis]
1Centre d'Esclerosi Múltiple de Catalunya, Hospital Universitari Vall d'Hebron, Barcelona, España. jrio@vhebron.net
Introduction And Development:
Natalizumab is a monoclonal antibody targeted against alpha-4 integrin that has proved to be very effective in the treatment of multiple sclerosis. The results of clinical trials published to date show a significant reduction in the rate of outbreaks and a decrease in the progression of the disability and of the disease activity as measured by means of magnetic resonance imaging. Natalizumab is well tolerated, although severe side effects have been reported that have conditioned its use as a second-line drug for the treatment of multiple sclerosis in patients who do not respond to conventional immunomodulators.
Conclusions:
The latest data in patients with these characteristics continue to show that natalizumab still offers a very good effectiveness and safety profile. This review examines the latest data on the response to natalizumab in patients who fail to respond to therapy with conventional drugs.
Related Concept Videos
Multiple Sclerosis l: Introduction
Respiratory Syncytial Virus Disease
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
